Open source automated insulin delivery systems: benefits, limitations and challenges in diabetes care

Open source closed loop automated insulin delivery (CL-AID) systems are increasingly used in the treatment of diabetes. Assembled on a do-it-yourself (DIY) basis, these systems integrate insulin pumps, continuous glucose monitoring devices, and algorithms that control the rate of insulin delivery based on glucose levels. In this review, we consider the technological features of open source CL-AID systems (OpenAPS, AndroidAPS, Loop, etc.), advantages and barriers to their use in clinical practice. Advantages of open source CL-AID systems over commercially available ones included lower cost, a choice of devices, a wide range of user settings, as well as continuous improvement of algorithms. A growing body of evidence indicates that open source CL-AID systems, such as OpenAPS, AndroidAPS, and Loop, provide an excellent time in range with minimal risk of hypoglycaemia and increase treatment satisfaction in patients with type 1 diabetes. A wide range of settings makes open source systems an effective tool for managing diabetes in situations with rapidly changing insulin requirement. However, some technological, medical, legal and ethical issues associated with the use of non-commercial CL-AID systems still need to be addressed. Assembling the system requires skills in diabetes technology. The issue of cybersecurity is also relevant. Lack of official approvals, low awareness of medical professionals, and reimbursement issues are slowing down the introduction of the technology into clinical practice. The professional medical community at the international and national levels needs to determine its position regarding the use of open source CL-AID systems in the treatment of diabetes.

1. Ware J, Hovorka R. Closed-loop insulin delivery: update on the state of the field and emerging technologies. Expert Rev Med Devices. 2022;19(11):859-875. doi: https://doi.org/10.1080/17434440.2022.2142556

2. Dovc K, Mutlu GY, Philippov YuI, et al. Free-living use of artificial pancreas for children with type 1 diabetes: systematic review. Diabetes mellitus. 2018;21(3):206-216. (In Russ.). doi: https://doi.org/10.14341/DM9714

3. Lewis DM, Hussain S. Practical guidance on open source and commercial automated insulin delivery systems: A guide for healthcare professionals supporting people with insulinrequiring diabetes. Diabetes Ther. 2022;13(9):1683-1699. doi: https://doi.org/10.1007/s13300-022-01299-9

4. Сорокин Д.Ю., Лаптев Д.Н. Некоммерческие системы введения инсулина в замкнутом контуре // Consilium Medicum. — 2020. — Т. 22. — №4. — С. 27-30. [Sorokin DYu, Laptev DN. Non-commercial insulin delivery closed-loop systems. Consilium Medicum 2020;22(4):27-30. (In Russ.)]. doi: https://doi.org/10.26442/20751753.2020.4.200117

5. Lewis D. History and perspective on DIY closed looping. J Diabetes Sci Technol. 2019;13(4):790-793. doi: https://doi.org/10.1177/1932296818808307

6. Litchman ML, Walker HR, Fitzgerald C, et al. PatientDriven Diabetes Technologies: Sentiment and Personas of the #WeAreNotWaiting and #OpenAPS Movements. J Diabetes Sci Technol. 2020;14(6):990-999. doi: https://doi.org/10.1177/1932296820932928

7. Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia. 2023;66(1):3-22. doi: https://doi.org/10.1007/s00125-022-05744-z

8. OpenAPS Reference Design [Internet]. Principles of an Open Artificial Pancreas System (OpenAPS) [cited 2023 Mar 05]. Available from: https://openaps.org/reference-design/

9. The AndroidAPS alt-Guide [Internet]. How OpenAPS works [cited 2023 Mar 05]. Available from: https://androidaps-altguide.readthedocs.io/en/latest/pages/OpenAPS_algorithm_basal.html/

10. The #OpenAPS community [Internet]. Welcome to OpenAPS’s documentation! [cited 2023 Mar 05]. Available from: https://openaps.readthedocs.io/

11. Ramkissoon CM, Herrero P, Bondia J, Vehi J. Unannounced meals in the artificial pancreas: Detection using continuous glucose monitoring. Sensors (Basel). 2018;18(3):884. doi: https://doi.org/10.3390/s18030884

12. Loop and Learn [Internet]. Free APS X [cited 2023 Mar 05]. Available from: https://www.loopandlearn.org/freeaps-x/

13. Loop and Learn [Internet] [cited 2023 Mar 05]. Available from: https://www.loopandlearn.org/

14. Tidepool [Internet] [cited 2023 Mar 05]. Available from: https://www.tidepool.org/tidepool-loop/

15. OMNIA [Internet] [cited 2023 Mar 05]. Available from: https://www.omnia.care/

16. The Nightscout project [Internet] [cited 2023 Mar 05]. Available from: http://www.nightscout.info/

17. Melmer A, Züger T, Lewis DM, et al. Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS). Diabetes Obes Metab. 2019;21(10):2333-2337. doi: https://doi.org/10.1111/dom.13810

18. Shahid A, Lewis DM. Large-scale data analysis for glucose variability outcomes with open-source automated insulin delivery systems. Nutrients. 2022;14(9):1906. doi: https://doi.org/10.3390/nu14091906

19. Patel R, Crabtree TSJ, Taylor N, et al. Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes. Diabet Med. 2022;39(5):e14793. doi: https://doi.org/10.1111/dme.14793

20. Toffanin C, Kozak M, Sumnik Z, et al. In Silico Trials of an OpenSource Android-Based Artificial Pancreas: A New Paradigm to Test Safety and Efficacy of Do-It-Yourself Systems. Diabetes Technol Ther. 2020;22(2):112-120. doi: https://doi.org/10.1089/dia.2019.0375

21. Gawrecki A, Zozulinska-Ziolkiewicz D, Michalak MA, et al. Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes. PLoS One. 2021;16(4):e0248965. doi: https://doi.org/10.1371/journal.pone.0248965

22. Lum JW, Bailey RJ, Barnes-Lomen V, et al. A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system. Diabetes Technol Ther. 2021;23(5):367-375. doi: https://doi.org/10.1089/dia.2020.0535

23. Volkova AR, Chernaya M, Vlasova K. Experience of using insulin therapy with the closed loop method among patients with type 1 diabetes mellitus in Russia. Endocrine Abstracts 2020;(70):AEP329. doi: https://doi.org/10.1530/endoabs.70.AEP329

24. Knoll C, Peacock S, Wäldchen M, et al. Real-world evidence on clinical outcomes of people with type 1 diabetes using open-source and commercial automated insulin dosing systems: A systematic review. Diabet Med. 2022;39(5):e14741. doi: https://doi.org/10.1111/dme.14741

25. Braune K, May A, Thurm U. Safe and successful completion of a half marathon by an adult with type 1 diabetes using a personalized open source artificial pancreas system. J Diabetes Sci Technol. 2020;14(6):1137-1138. doi: https://doi.org/10.1177/1932296819884922

26. Ahmed SH, Gallo S. Looping with do-it-yourself artificial pancreas systems during ramadan fasting in type 1 diabetes mellitus: Perspectives of a user and a physician. Diabetes Ther. 2020;11(11):2453-2463. doi: https://doi.org/10.1007/s13300-020-00901-2

27. Schütz AK, Schütz-Fuhrmann I, Stadler M, et al. Management of type 1 diabetes mellitus using open-source automated insulin delivery during pregnancy: A case series. Diabetes Technol Ther. 2022;24(3):227-230. doi: https://doi.org/10.1089/dia.2021.0260

28. Lemieux P, Yamamoto JM, Donovan LE. Do-it-yourself artificial pancreas system use in pregnant women with type 1 diabetes in a real-world setting: 2 case reports. Can J Diabetes. 2021;45(8):804-808.e2. doi: https://doi.org/10.1016/j.jcjd.2021.01.006

29. Ahmed SH, Ewins DL, Bridges J, et al. Do-It-Yourself (DIY) artificial pancreas systems for type 1 diabetes: perspectives of two adult users, parent of a user and healthcare professionals. Adv Ther. 2020;37(9):3929-3941. doi: https://doi.org/10.1007/s12325-020-01431-w

30. Jeyaventhan R, Gallen G, Choudhary P, Hussain S. A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G. Diabetes Obes Metab. 2021;23(8):1989-1994. doi: https://doi.org/10.1111/dom.14439

31. Asarani NAM, Reynolds AN, Elbalshy M, et al. Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: a systematic review. Acta Diabetol. 2021;58(5):539-547. doi: https://doi.org/10.1007/s00592-020-01623-4

32. Burnside M, Lewis D, Crocket H, et al. CREATE (Community deRivEd AutomaTEd insulin delivery) trial. Randomised parallel arm open label clinical trial comparing automated insulin delivery using a mobile controller (AnyDANA-loop) with an opensource algorithm with sensor augmented pump therapy in type 1 diabetes. J Diabetes Metab Disord. 2020;19(2):1615-1629. doi: https://doi.org/10.1007/s40200-020-00547-8

33. Burnside MJ, Lewis DM, Crocket HR, et al. Open-source automated insulin delivery in type 1 diabetes. N Engl J Med. 2022;387(10):869-881. doi: https://doi.org/10.1056/NEJMoa2203913

34. Nanayakkara N, Sharifi A, Burren D, et al. Hybrid closed loop using a do-it-yourself artificial pancreas system in adults with type 1 diabetes. J Diabetes Sci Technol. 2023:193229682311538. doi: https://doi.org/10.1177/19322968231153882

35. Petruzelkova L, Neuman V, Plachy L, et al. First use of open-source automated insulin delivery AndroidAPS in full closed-loop scenario: Pancreas4ALL randomized pilot study. Diabetes Technol Ther. 2023;25(5):315-323. doi: https://doi.org/10.1089/dia.2022.0562

36. O’Donnell S, Cooper D, Chen Y, et al. Barriers to uptake of Open-Source automated insulin delivery Systems: Analysis of socioeconomic factors and perceived challenges of adults with type 1 diabetes from the OPEN survey. Diabetes Res Clin Pract. 2023;197(5):110235. doi: https://doi.org/10.1016/j.diabres.2022.110235

37. Murray JA, Clayton MF, Litchman ML. Health care provider knowledge and perceptions of fda-approved and do-it-yourself automated insulin delivery. J Diabetes Sci Technol. 2020;14(6):1017-1021. doi: https://doi.org/10.1177/1932296819895567

38. Crabtree TSJ, Choudhary P, Hammond P, et al. Health-care professional opinions of DIY artificial pancreas systems in the UK. Lancet Diabetes Endocrinol. 2020;8(3):186-187. doi: https://doi.org/10.1016/S2213-8587(19)30417-6

39. O’Keeffe DT, Maraka S, Basu A, et al. Cybersecurity in artificial pancreas experiments. Diabetes Technol Ther. 2015;17(9):664-666. doi: https://doi.org/10.1089/dia.2014.0328

40. Lazaro C, Oruklu E, Cinar A. Security challenges and solutions for closedloop artificial pancreas systems. In: 2017 IEEE 60th International Midwest Symposium on Circuits and Systems (MWSCAS). Vol 197. IEEE; 2017. P. 1097-1100. doi: https://doi.org/10.1109/MWSCAS.2017.8053119

41. Heinemann L, Lange K. «Do It Yourself» (DIY)-Automated Insulin Delivery (AID) systems: current status from a German point of view. J Diabetes Sci Technol. 2020;14(6):1028-1034. doi: https://doi.org/10.1177/1932296819889641

42. Duke MD, Fredlock AA. Do-It-Yourself (DIY) systems in diabetes: A family and provider perspective. J Diabetes Sci Technol. 2020;14(5):917-921. doi: https://doi.org/10.1177/1932296820906204

43. Lewis DM, Hussain S. Practical guidance on open source and commercial automated insulin delivery systems: A guide for healthcare professionals supporting people with insulinrequiring diabetes. Diabetes Ther. 2022;13(9):1683-1699. doi: https://doi.org/10.1007/s13300-022-01299-9